PARP1 and cancer: Similarly other mutations that increase RS through activation of oncogenes or inactivation of tumor suppressors maintaining genome stability leave cancers vulnerable to a whole new class of drugs such as PARP (PARPi) and CHK1 (CHK1i) inhibitors.